This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

Neoplasms Clinical Trial

Official title:

An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 905677 Administered Intravenously in Patients With Advanced Solid Tumours

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03604445
• Other study ID #: 1401-0001
• Secondary ID: 2017-002945-31
• Status: Terminated
• Phase: Phase 1
• Start date: August 8, 2018
• Est. completion date: July 27, 2022

Study information

• Verified date: July 2023
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is open to adults with different types of advanced cancer (solid tumours). This study is open to people in whom previous treatments were not successful. The purpose of this study is to find out the highest dose of BI 905677 the participants can tolerate. BI 905677 is a type of an antibody that is being developed to treat cancer.

One dose of BI 905677 is given to the participants every 2 or 3 weeks as infusion into a vein. In this study, BI 905677 is given to humans for the first time. The participants visit the study site at least once a week so that the doctors can check their general health. The participants are in the study for as long as they benefit from and can tolerate treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 37
• Est. completion date: July 27, 2022
• Est. primary completion date: July 27, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

• Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-haematologic malignancy. Patient must have measurable or evaluable lesions (according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1).

• Patient who has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted treatment options known to prolong survival for their disease.

• Patient willing to undergo mandatory skin biopsy at the timepoints specified in the protocol.

• Eastern Cooperative Oncology Group score of 0 or 1.

• Adequate organ function defined as all of the following:

• Absolute neutrophil count (ANC) = 1.5 x 109/L; haemoglobin = 9.0 g/dL; platelets = 100 x 109/L without the use of hematopoietic growth factors within 4 weeks of start of study medication.

• Total bilirubin = 1.5 times the upper limit of normal (ULN), except for patients with Gilbert's syndrome: total bilirubin = 3 x ULN or direct bilirubin = 1.5 x ULN.

• Creatinine = 1.5 x ULN. If creatinine is > 1.5 x ULN, patient is eligible if concurrent creatinine clearance = 50 ml/min (measured or calculated by CKDEPI formula or Japanese version of CKD-EPI formula for Japanese patients).

• Aspartate transaminase (AST) and alanine transaminase (ALT) = 3 x ULN if no demonstrable liver metastases, or otherwise = 5 x ULN

• Alkaline Phosphatase < 5 x ULN

• Recovered from any previous therapy-related toxicity to = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at start of treatment (except for alopecia and stable sensory neuropathy which must be = CTCAE Grade 2).

• At least 18 years of age at the time of consent or over the legal age of consent in countries where that is greater than 18 years.

• Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.

• Life expectancy = 3 months at the start of treatment in the opinion of the investigator.

• Male or female patients. Women of childbearing potential (WOCBP) must only be included after a confirmed menstrual period within the past 4 weeks and a negative pregnancy test at screening. WOCBP with irregular menstruation may be included after two negative pregnancy tests during screening between 2 and 4 weeks apart. WOCBP and men who are able to father a child must be ready and able to use highly effective methods of birth control, per ICH M3 (R2), that result in a low failure rate of less than 1% per year when used consistently and correctly. These methods must be used during the study and for at least 6 months after the last dose of BI 905677. A list of contraception methods meeting these criteria is provided in the patient information.

Exclusion criteria

• Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first trial treatment or planned within 6 months after screening.

• Previous or concomitant malignancies other than the one treated in this trial within the last 2 years, except;

• effectively treated non-melanoma skin cancers

• effectively treated carcinoma in situ of the cervix

• effectively treated ductal carcinoma in situ

• other effectively treated malignancy that is considered cured by local treatment

• Osteoporosis = Common Terminology Criteria for Adverse Events (CTCAE) Grade 2

• Chronic corticosteroid use

• Osteoporotic compression fracture within 12 months prior to informed consent which is clinically significant in the opinion of the investigator.

• Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.

• Previous treatment in this trial.

• Treatment with a systemic anti-cancer therapy or investigational drug within 28 days or 5 half-lives (whichever is shorter) of the first treatment with the study medication.

• Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the safety and efficacy of the test drug.

• Women who are pregnant, nursing, or who plan to become pregnant or nurse during the trial or within 6 months after the last dose of study treatment.

• Active alcohol or drug abuse in the opinion of the investigator.

• Patient unwilling or unable to comply with the protocol.

• Presence or history of uncontrolled or symptomatic brain or subdural metastases, unless considered stable by the investigator and local therapy was completed. Inclusion of patients with newly identified brain metastasis/es at screening will be allowed if patients are asymptomatic.

• Known history of human immunodeficiency virus (HIV) infection or an active hepatitis B or C infection which in the opinion of the investigator may interfere with participation in the trial.

• History of severe hypersensitivity reactions to monoclonal antibodies.

• History of allergy to kanamycin or similar class drugs (including streptomycin, gentamicin, amikacin, tobramycin and neomycin).

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• BI 905677
Solution for infusion

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital East	Chiba, Kashiwa
Netherlands	Erasmus MC Kanker Instituut	Rotterdam
Spain	Hospital Vall d'Hebron	Barcelona
United States	University of Southern California	Los Angeles	California
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Japan,  Netherlands,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Dose Limiting Toxicities (DLTs)	The number of participants with Dose Limiting Toxicities (DLTs) is reported. Any of the following adverse events (AEs) will be classified as DLTs following review by the Safety Monitoring Committee and the Medical Monitor, unless unequivocally due to underlying malignancy or an extraneous cause, including any AE which prevents a patient starting Cycle 2 within 14 days of completion of Cycle 1; Bone mineral density change of >5% from baseline, confirmed at least 2 months after initial observation; ß-CTX increase of more than two-fold from baseline; Grade 3 osteoporosis, and so on.	In the first treatment cycle, up to 3 weeks
Primary	Number of Patients Experiencing Adverse Events (AEs) During the Entire Treatment Period	The Number of patients experiencing adverse events (AEs) during the entire treatment period is reported.	From first dose until last dose + 42 days (6 weeks) of residual effect period, up to 36 weeks.
Secondary	Maximum Measured Concentration of BI 905677 in Serum After First Infusion (Cmax)	The Maximum measured concentration of BI 905677 in serum after first infusion is reported.	5 minutes (min) before and at 1, 1.5, 4, 8, 24, 72, 168 and 336 hour(s) after first dosing in Cycle 1.
Secondary	Area Under the Serum Concentration-time Curve Over the Time Interval From 0 to the Last Measured Time Point (AUC0-tz)	The Area under the serum concentration-time curve over the time interval from 0 to the last measured time point is reported.	5 minutes (min) before and at 1 1.5, 4, 8, 24, 72, 168 and 336 hour(s) after first dosing in Cycle 1.

External Links

•   Related Info